Welcome to the HAE Expert Hub
Welcome to the HAE Expert Hub
A dynamic platform designed to inform and inspire, where you can stay up to date on the latest developments on HAE treatments, ANDEMBRY® (garadacimab) and BERINERT® (C1-esterase inhibitor, human)
ANDEMBRY® (garadacimab) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.1
BERINERT® (C1-esterase inhibitor, human) for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (HAE) attacks in adolescent and adult patients with C1-esterase inhibitor deficiency.2,3
Featured content
Featured content
HAE EXPERT HUB
Get leading HAE expert opinions
Hear HAE experts discuss the clinical evidence supporting the approval of ANDEMBRY®, as well as real-world patient case studies.
More resources
More resources
Learn how ANDEMBRY® is changing the path in HAE
Review key clinical data and the mechanism of action for ANDEMBRY®.
Access helpful tools and resources to support patients with HAE
Explore new ways to help your patients navigate their treatment with ANDEMBRY® and BERINERT®.
Access e-learning via the HAE Academy
Access CPD-accredited training materials and e-learning content on the diagnosis, treatment and management of HAE.
Explore More
Explore More
Explore HAE attack reduction with ANDEMBRY® (VANGUARD)
Review key efficacy data from the pivotal phase 3 VANGUARD trial for ANDEMBRY®.
Review the safety and tolerability profile of ANDEMBRY®
View safety data from the VANGUARD trial and OLE.
Explore how to administer ANDEMBRY®
Discover convenient and consistent dosing with ANDEMBRY®.
Abbreviations: CPD, Continuing Professional Development; HAE, hereditary angioedema; OLE, open-label extension.
References:
1. ANDEMBRY® (garadacimab). Summary of Product Characteristics.
2. BERINERT® 2000 IU (C1-esterase inhibitor, human). Summary of Product Characteristics.
3. BERINERT® 3000 IU (C1-esterase inhibitor, human). Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple store. Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447405.
GBR-AND-0314 | May 2026.